Tag: Atai Life Sciences - Page 8 - Psychedelic Alpha

Read more about the article ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic

Post published:October 27, 2020
Post category:Press Release

Read more about the article ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product

ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product

Post published:August 24, 2020
Post category:Press Release

Read more about the article IntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based Psychedelics

IntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based Psychedelics

Post published:August 20, 2020
Post category:Press Release

Read more about the article ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse

ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse

Post published:July 9, 2020
Post category:Press Release

Read more about the article UBS Private Markets Newsletter Features ATAI Guest Piece

UBS Private Markets Newsletter Features ATAI Guest Piece

Post published:May 18, 2020
Post category:News

Read more about the article New York Times runs an article on VC interest in psychedelic medicines, including psilocybin

New York Times runs an article on VC interest in psychedelic medicines, including psilocybin

Post published:March 6, 2020
Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.